• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Science: A Fortnightly Journal of Research >Anti-tumour and immune enhancing activities of MLAA-22(379-387) on acute myeloid leukemia
【24h】

Anti-tumour and immune enhancing activities of MLAA-22(379-387) on acute myeloid leukemia

机译：MLAA-22（379-387）对急性髓性白血病的抗肿瘤和免疫增强活性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We have earlier demonstrated that MLAA-22(379-387) is a novel, acute, monocytic, leukemia-associated antigen epitope in vitro. In this study, the effect and mechanism of MLAA-22(379-387) on animals have been further examined. We found that tumour weight and volume had significantly decreased in SCID-injected THP-1 mice with MLAA-22(379-387) treatment for two weeks. MLAA-22(379-387) induced cytotoxic T lymphocytes (CTL) activity in A549, MCF-7, THP-1, U937 and T2 cells, especially significant CTL activity at effector/target ratio of 50 : 1 in THP-1 cells. The percentage of CD3 + CD8 + T cells had significantly increased, while the percentage of CD4 + CD25 + T cells had significantly decreased in MLAA-22(379-387) treatment group compared to other groups. Levels of IL-2, IFN-gamma and IgG had significantly increased, but levels of TGF-beta and IL-10 had significantly decreased after MLAA-22(379-387) vaccination for two weeks. Thus, we may conclude that MLAA-22(379-387) treatment effectively improves the immune system, thus indicating tumouricidal capacity in leukaemic mice. These findings highlight the potential application of MLAA-22(379-387) as an efficient target for immunotherapy in acute myeloid leukemia.
机译：我们早些时候表明MLAA-22（379-387）是一种新型，急性，单核细胞白血病相关的抗原表位体外。在该研究中，进一步研究了MLAA-22（379-387）对动物的影响和机制。我们发现，SCID注入的THP-1小鼠与MLAA-22（379-387）治疗肿瘤重量和体积显着降低了两周。 MLAA-22（379-387）在A549，MCF-7，THP-1，U937和T2细胞中诱导细胞毒性T淋巴细胞（CTL）活性，尤其是THP-1细胞效应/目标比例为50：1的显着CTL活性。 CD3 + CD8 + T细胞的百分比显着增加，而与其他基团相比，MLAA-22（379-387）治疗组的CD4 + CD25 + T细胞的百分比显着降低。 IL-2，IFN-Gamma和IgG的水平显着增加，但在MLAA-22（379-387）疫苗接种后，TGF-β和IL-10的水平显着降低了两周。因此，我们可以得出结论，MLAA-22（379-387）治疗有效改善免疫系统，从而表明睫毛小鼠的血管碱能力。这些发现突出了MLAA-22（379-387）作为急性髓性白血病免疫疗法的有效靶标的潜在应用。

著录项

  • 来源
  • 作者

    Li Jing; Zhang Wanggang; Bai Ju; Zhong Bo; Wang Huiyuan; Geng Yan; Jin Qiaoyan; Hao Juanjuan; Zhang Yang;

  • 作者单位

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Hematol Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Hematol Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

    Xi An Jiao Tong Univ Med Sch Affiliated Hosp 2 Dept Pediat Xian Xincheng Xiwu Rd 157 Xian 710004 Shaanxi Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 自然科学现状及发展;
  • 关键词

    Acute myeloid leukemia; anti-tumour activity; immunotherapy; mice;

    机译：急性髓性白血病;抗肿瘤活性;免疫疗法;小鼠;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号